Biorepository & Tissue Analysis Shared Resource

   
Selected Publications:

1.Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS ONE 8(3):e57911, 2013. PMCID: PMC3607594
View in: PubMed

2.Talwar S, Balasubramanian S, Sundaramurthy S, House R, Wilusz CJ, Kuppuswamy D, D'Silva N, Gillespie MB, Hill EG, Palanisamy V. Overexpression of RNA-binding protein CELF1 prevents apoptosis and destabilizes pro-apoptotic mRNAs in oral cancer cells. RNA Biol 10(2):277-86, 2013. PMCID: PMC3594286
View in: PubMed

3.Byrd JK, Wilhoit CS, Fordham MT, Reeves TD, McCrackan TR, Nguyen SA, Sutkowski N, Gillespie MB. Predicting HPV Status in Head and Neck Cancer: The Predictive Value of Sociodemographic and Disease Characteristics. Arch. Otolaryngol. Head Neck Surg. 138(12):1155-9, 2012.
View in: PubMed

4.Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 5(1):105-21, 2013. PMCID: PMC3569657
View in: PubMed

5.Pandey JP, Namboodiri AM, Kistner-Griffin E. A genetic variant of FcγRIIIa is strongly associatedwith humoral immunity to cyclin B1 in African American patients with prostate cancer. Immunogenetics 65(2):91-6, 2013.
View in: PubMed

6.Beckham TH, Lu P, Jones EE, Marrison T, Lewis CS, Cheng JC, Ramshesh VK, Beeson G, Beeson CC, Drake RR, Bielawska A, Bielawski J, Szulc ZM, Ogretmen B, Norris JS, Liu X. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J. Pharmacol. Exp. Ther. 344(1):167-78, 2013. PMCID: PMC3533418
View in: PubMed

7.Hossain A, Radwan FF, Doonan BP, God JM, Zhang L, Bell PD, Haque A. A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis 17(10):1066-78, 2012. PMCID: PMC3747633
View in: PubMed

8.Sentelle RD, Senkal CE, Jiang W, Ponnusamy S, Gencer S, Selvam SP, Ramshesh VK, Peterson YK, Lemasters JJ, Szulc ZM, Bielawski J, Ogretmen B. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat. Chem. Biol. 8(10):831-8, 2012. PMCID: PMC3689583
View in: PubMed

9.Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, Shao Y, Sabbadini R, Ogretmen B. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 4(8):761-75, 2012. PMCID: PMC3494075
View in: PubMed

10.Beckham TH, Lu P, Cheng JC, Zhao D, Turner LS, Zhang X, Hoffman S, Armeson KE, Liu A, Marrison T, Hannun YA, Liu X. Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B. Int. J. Cancer 131(9):2034-43, 2012. PMCID: PMC3384773
View in: PubMed

11.Grek CL, Townsend DM, Uys JD, Manevich Y, Coker WJ, Pazoles CJ, Tew KD. S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs. Cancer Res. 72(9):2383-93, 2012.
View in: PubMed

12.Nguyen SA, Walker D, Gillespie MB, Gutkind JS, Day TA. mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma. Curr Treat Options Oncol 13(1):71-81, 2012.
View in: PubMed

13.Sambandam Y, Sundaram K, Liu A, Kirkwood KL, Ries WL, Reddy SV. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene 32(1):97-105, 2013. PMCID: PMC3355224
View in: PubMed

14.Smith AM, Findlay VJ, Bandurraga SG, Kistner-Griffin E, Spruill LS, Liu A, Golshayan AR, Turner DP. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype. Carcinogenesis 33(3):572-80, 2012.
View in: PubMed

15.Meyers-Needham M, Ponnusamy S, Gencer S, Jiang W, Thomas RJ, Senkal CE, Ogretmen B. Concerted functions of HDAC1 and microRNA-574-5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells. EMBO Mol Med 4(2):78-92, 2012. PMCID: PMC3376837
View in: PubMed

16.Hossain A, God JM, Radwan FF, Amria S, Zhao D, Bethard JR, Haque A. HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition. Clin. Dev. Immunol. 2011:780839, 2011. PMCID: PMC3227386
View in: PubMed

17.Little EC, Wang C, Watson PM, Watson DK, Cole DJ, Camp ER. Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J. Surg. Res. 176(2):359-66, 2012. PMCID: PMC3406409
View in: PubMed

18.Sharma S, Gillespie BM, Palanisamy V, Gimzewski JK. Quantitative nanostructural and single-molecule force spectroscopy biomolecular analysis of human-saliva-derived exosomes. Langmuir 27(23):14394-400, 2011. PMCID: PMC3235036
View in: PubMed

19.Talwar S, Jin J, Carroll B, Liu A, Gillespie MB, Palanisamy V. Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress. J. Biol. Chem. 286(37):32333-43, 2011. PMCID: PMC3173192
View in: PubMed

20.Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response. Clin. Cancer Res. 17(18):6097-105, 2011. PMCID: PMC3176980
View in: PubMed

21.Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart R, Perrotti D, Ogretmen B. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 117(22):5941-52, 2011. PMCID: PMC3112039
View in: PubMed

22.Turner DP, Findlay VJ, Moussa O, Semenchenko VI, Watson PM, LaRue AC, Desouki MM, Fraig M, Watson DK. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 71(16):1723-35, 2011. PMCID: PMC3128180
View in: PubMed

23.Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS ONE 6(3):e17649, 2011. PMCID: PMC3050925
View in: PubMed

24.Oleinik NV, Krupenko NI, Krupenko SA. Epigenetic Silencing of ALDH1L1, a Metabolic Regulator of Cellular Proliferation, in Cancers. Genes Cancer 2(2):130-9, 2011. PMCID: PMC3111244
View in: PubMed

25.Li Q, Yu H, Zinna R, Martin K, Herbert B, Liu A, Rossa C, Kirkwood KL. Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss. J. Pharmacol. Exp. Ther. 336(3):633-42, 2011. PMCID: PMC3061533
View in: PubMed

26.Mack JT, Helke KL, Normand G, Green C, Townsend DM, Tew KD. ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration. Cancer Lett. 300(2):154-61, 2011. PMCID: PMC2994978
View in: PubMed

27.Lucas JT, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 29(31):4449-59, 2010. PMCID: PMC2921319
View in: PubMed

28.Walsh JE, Clark AM, Day TA, Gillespie MB, Young MR. Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum. Immunol. 71(7):659-65, 2010. PMCID: PMC3337687
View in: PubMed

29.Moussa O, Turner DP, Feldman RJ, Sementchenko VI, McCarragher BD, Desouki MM, Fraig M, Watson DK. PDEF is a negative regulator of colon cancer cell growth and migration. J. Cell. Biochem. 108(6):1389-98, 2009. PMCID: PMC3348703
View in: PubMed

30.Gillespie MB, Rubinchik S, Hoel B, Sutkowski N. Human papillomavirus and oropharyngeal cancer: what you need to know in 2009. Curr Treat Options Oncol 10(5-6):296-307, 2009.
View in: PubMed

31.Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum. Immunol. 70(6):375-82, 2009. PMCID: PMC2746465
View in: PubMed

32.Kulbersh JS, Day TA, Gillespie MB, Young MR. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. Otolaryngol Head Neck Surg 140(2):235-40, 2009. PMCID: PMC3337726
View in: PubMed

33.Gillespie MB, Smith J, Gibbs K, McRackan T, Rubinchik S, Day TA, Sutkowski N. Human papillomavirus and head and neck cancer: a growing concern. J S C Med Assoc 104(8):247-51, 2008.
View in: PubMed

34.Findlay VJ, Turner DP, Moussa O, Watson DK. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Res. 68(20):8499-506, 2008. PMCID: PMC2680499
View in: PubMed

35.Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, Watson DK. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res. 68(11):4097-104, 2008.
View in: PubMed

36.Townsend DM, He L, Hutchens S, Garrett TE, Pazoles CJ, Tew KD. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res. 68(8):2870-7, 2008. PMCID: PMC3397193
View in: PubMed

37.Amria S, Cameron C, Stuart R, Haque A. Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk. Lymphoma 49(2):353-5, 2008.
View in: PubMed

38.Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK, Boylan AM. CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am. J. Respir. Cell Mol. Biol. 38(6):671-8, 2008. PMCID: PMC2396246
View in: PubMed

39.Younger AR, Amria S, Jeffrey WA, Mahdy AE, Goldstein OG, Norris JS, Haque A. HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis. 11(4):334-41, 2008.
View in: PubMed

40.Moussa O, Riker JM, Klein J, Fraig M, Halushka PV, Watson DK. Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 27(1):55-62, 2008.
View in: PubMed